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ABSTRACT 28 
BACKGROUND 29 
Antimicrobial stewardship aims to optimise antibiotic use and mimimise selection of antimicrobial 30 
resistance. Many published studies in this field suffer from methodological limitations. 31 
OBJECTIVES: 32 
The objective of this study was to perform a comprehensive systematic review of antimicrobial 33 
stewardship evaluations focusing on study design quality. 34 
DATA SOURCES: 35 
The following online database was searched: PubMed. 36 
 37 
STUDY ELIGIBILITY CRITERIA:Studies published between January 1950 and January 2017, evaluating 38 
any antimicrobial stewardship intervention in the community or  hospital setting, without restriction on 39 
study design or outcome. 40 
 41 
METHODS 42 
We extracted data on pre-specified design quality features and contingencies that may influence design 43 
choices including: (1) clinical setting, (2) age group studied, (3) when the study was conducted, (4) 44 
geographical region and (5) financial support received. 45 
 46 
RESULTS 47 
The initial search yielded 17,382 articles; 1,008 were selected for full-text screening, of which 825 were 48 
included. Most studies (675/825, 82%) were non-experimental and 104 (15%) of these used interrupted 49 
time series analysis, 41 (6%) used external controls and 19 (3%) used both. Studies in the community 50 
setting fulfilled a median of 5/10 quality features (IQR 3-7) and 3 (IQR 2-4) in the hospital setting. 51 
Community setting studies (25%, 205/825)were significantly more likely to use randomisation (OR 5.9 52 
(95%CI 3.8-9.2)), external controls (OR 5.6 (95%CI 3.6-8.5)) and multiple centres (OR 10.5 (95%CI 7.1-53 
15.7)). From all studies, only 48% (398/825) reported clinical and 23% (190/825) reported microbiological 54 
outcomes.  Quality did not improve over time.  55 
 56 
CONCLUSIONS 57 
Overall, design quality of studies evaluating antimicrobial stewardship interventions is low and has not 58 
improved in the past years. Most published studies do not report clinical and microbiological outcome 59 
data. Studies conducted in the community setting were associated with better quality. These limitations 60 
should inform the design of future stewardship evaluations so that a robust evidence base can be built to 61 
guide clinical practice.    62 
INTRODUCTION 63 
Antimicrobial resistance (AMR) is increasing globally and is a substantial threat to human health[1]. There 64 
is a clear relationship between antibiotic exposure and AMR both in populations [2] and individual patients 65 
[3]. An estimated 30% of human antibiotic use may be unnecessary and healthcare systems around the 66 
world are aiming to achieve substantial reductions in unnecessary antibiotic prescribing. The term 67 
‘antimicrobial stewardship’ is used to describe use of antibiotics which balances the need for effective 68 
individual treatment against the longer-term, societal impact of antibiotic use on antibiotic resistance[4]. 69 
Interventions to improve antimicrobial stewardship are usually multifaceted and include periodic or 70 
individual patient audit and feedback, decision support, education (educational meetings, educational 71 
materials), and antimicrobial formulary restriction[5]. 72 
Recognition of the threat posed by AMR and the need to optimise antibiotic prescribing has driven an 73 
exponential increase in the publication of studies evaluating antimicrobial stewardship interventions over 74 
the last 20 years[6]. Previous systematic reviews have synthesised this evidence with the aim of making 75 
recommendations for practice[5,7–12].  These have, appropriately, considered studies with the lowest 76 
possible risk of bias but have excluded >50% of published studies in which methodological quality falls 77 
below Effective Practice and Organisation of Care (EPOC) criteria[13]. Because the minority of studies 78 
are of sufficient quality, many areas of practice rely on a weak evidence base [8]; conducting studies 79 
which do not inform practice is a waste of time and valuable resources [5,12].  80 
Journals are beginning to report the minimum standards for antimicrobial stewardship studies to be 81 
published [14]; however, there remains a need for consensus on how to design, analyse and report 82 
studies evaluating interventions to improve antibiotic prescribing. This would optimise use of valuable 83 
resources and strengthen the evidence base in this field. Currently, no overview exists of how 84 
antimicrobial stewardship evaluations are designed. We conducted a systematic review of antimicrobial 85 
stewardship evaluations with the aim of identifying those areas in stewardship evaluation most in need of 86 
improvement,  to increase validity and translation of research findings into clinical practice. 87 
 88 
METHODS 89 
Search strategy 90 
We searched PubMed for studies evaluating antimicrobial stewardship interventions between January 91 
1950 and January 2017. The search strategy (appendix 1) was designed to be as broad as possible. 92 
Inclusion criteria were: any study evaluating an antimicrobial stewardship intervention, without restriction 93 
on the type of intervention studied and what outcomes were evaluated. Studies were excluded if they 94 
were (1) not in English, (2) case-reports, (3) focused mainly on HIV or (4) narrative or systematic reviews. 95 
All studies were screened by one author (VAS, CHvW, JI, KH or IvH). In case of duplicate publications, 96 
only the original article was included. A random selection of 700 (~4% of total) studies were assessed by 97 
a second author (VAS, CHvW, JI, KH or IvH). Uncertainties about the inclusion of studies was resolved by 98 
discussion.   99 
 100 
Data extraction 101 
Studies fulfilling the inclusion criteria were identified by screening on title and abstract. All selected 102 
studies then underwent full-text evaluation by one author (VAS, CHvW, JI, KH or IvH) against the 103 
inclusion and exclusion criteria and data was subsequently extracted using a standard data extraction 104 
template (appendix 2). Data were extracted on study characteristics (i.e. title, authors, year of 105 
publication), design quality features, and contingencies possibly associated with methodological quality. If 106 
no funding was reported it was assumed that studies received no financial support. Authors were not 107 
contacted in case data were missing or incomplete. A random selection of 10% of the studies were 108 
extracted by a second author. We followed the PRISMA criteria for the reporting of systematic reviews 109 
(appendix 3) [15]. 110 
 111 
Selection of quality features, and contingencies 112 
In February 2017 we established an international Consensus Working Group funded by the Joint 113 
Programming Initiative on Antimicrobial Resistance (JPIAMRWG-010) to develop recommendations on 114 
the design, analysis and reporting of antimicrobial stewardship evaluations. The working group 115 
coordinators (VAS, CHvW, ML, ASW, MB) invited members to the consensus group based on their 116 
experise on antimicrobial stewardship and/or trial methodology, ensuring that all key clinical areas 117 
(primary care, secondary care, intensive care medicine and paediatrics) were represented.  The 118 
consensus group agreed that a review to identify areas in stewardship evaluation most in need of 119 
improvement to increase validity and translation of research findings into clinical practice was required. 120 
For this purpose, existing quality scores were not applicable because these focus solelyon 121 
methodological quality. The group selected quality features and contingencies likely to underlie design 122 
quality and  features based on plenary group discussion during the consensus meeting. Ten quality 123 
features were selected for assessment: (1) randomized research design used, (2) external control group 124 
assessed, (3) multiple centres used, (4) sustainability of the intervention sufficiently assessed (≥12 125 
months), (5) sample size calculation reported, (6) prospective data collection, (7) correction for 126 
confounding factors, (8) primary outcome defined and reported, (9) clinical outcome reported, and (10) 127 
microbiological outcome reported.. Selected contingencies likely to underlie design quality features were 128 
(a) the clinical setting (community versus hospital), (b) age group studied (studies including children 129 
versus adults, or both), (c) year when study was conducted (newer versus older studies, categorised at 130 
approximate quintiles: 1977-2004, 2005-2010, 2011-2013, 2014-2015, 2016-2017) (d) geographical 131 
region, and (e) financial support. The quality features and corresponding categorizations are shown in 132 
table S1. 133 
 134 
Statistical analysis 135 
Descriptive statistics were used to describe the quality features of included studies. Differences stratified 136 
by subgroup were displayed using spider graphs (Microsoft Excel, version 2010). To assess the 137 
independent relationship between contingencies and quality features we performed multivariable logistic 138 
regression models with backward stepwise selection (exit p-value >0.10), presenting odds ratios and 95% 139 
confidence intervals in a heatmap displaying the strength of the association (Microsoft Excel, version 140 
2010). Analyses were performed using the Statistical Package for the Social Sciences for Windows 141 
(Version SPSS 21.0.0.0). 142 
 143 
RESULTS 144 
The initial search yielded 17,382 articles. After title and abstract screening, 1,008 articles were selected 145 
for full-text screening (figure 1). Of these, 183 were excluded leaving 825 articles for full assessment 146 
(appendix 4). Among 700 randomly selected articles that were screened by a second author, 640/700 147 
(91%) were excluded by both authors, 23/700 (3.3%) were selected for inclusion by both authors, 13/700 148 
(1.8%) were selected for inclusion by only the first author, and 24/700 (3.4%) were selected for inclusion 149 
by only the second author, resulting in a percentage agreement after title/abstract screening of 95%, with 150 
a moderate interobserver agreement (Cohen’s kappa: 0.53). After discussion of the fulltext articles, 151 
consensus about inclusion was reached in 99.5% (696/700) of the selected articles. From the 3.4% 152 
(24/700) studies that were newly identified by a second author, 7/700 (1.0%) were considered correct 153 
inclusions after discussion. Therefore, the low proportion of missed papers justified not screening in 154 
duplicate. Among the 83 selected articles from which data was extracted by a second author, the 155 
percentage agreement per variable ranged from 91%-100%, with all the quality features showing an 156 
agreement of ≥95%. 157 
 158 
Characteristics of included studies 159 
A total of 825 studies were included, In the community setting, most studies were multicenter (72%, 160 
148/205) and the commonest study designs were before-after studies without an interrupted time-series 161 
(ITS) analysis (23%, 48/205), randomised controlled trials (14%, 28/205), and parallel cluster randomised 162 
trials (15%, 30/205)(Table 1). Among the included studies in the hospital setting, most were single centre 163 
(16%, 101/620) and the commonest study designs were before-after studies without an ITS analysis 164 
(59%, 365/620), before-after studies with an ITS analysis (13%, 82/620), and cohort studies without a 165 
control group (12%, 75/620. Among the before-after studies without an ITS analysis, the majority were 166 
single centre (86%, 352/411), and retrospective (58%, 239/411). In the 86 (10%) cluster randomised 167 
studies a median of 28 clusters were randomised, with 57% (49/86) randomising ≥20 clusters, 28% 168 
(24/86) randomising <15 clusters, 21% (18/86) randomising <10 clusters, and 9% (8/86) randomising <5 169 
clusters. In the hospital setting, 13% (2/13) randomised ≥20 clusters, while in the community setting 65% 170 
(64/71) randomised ≥20 clusters. A minority of studies were conducted in children (12%, 101/825). Both 171 
in the community and the hospital setting, most studies did not target a specific disease or syndrome 172 
(31%, 63/205, 55% 324/620, respectively) or specific antibiotic class (86%, 177/205, 69% 427/620, 173 
respectively). The majority of interventions were bundles (57%, 470/825). Commonest interventions in the 174 
community setting included education (73%, 149/205), audit with periodic feedback (29%, 59/205), and 175 
clinical decision support 15% (31/205). In the hospital setting, commonest interventions included 176 
education 42% (260/620), audit and feedback on an individual patient level (40%, 245/620), restriction 177 
(18%, 113/620), and clinical decision support (18%, 112/620). Both in the community and hospital setting, 178 
virtually all included studies reported process measure outcomes (99%, 818/825) (Table 2). Both in the 179 
community setting and the hospital the most commonly reported process measures included the 180 
proportion of patients treated with antibiotics (59%, 121/205, 21%, 131/620), costs/cost-effectiveness 181 
(18%, 36/205, 32%, 200/620, respectively), appropriateness (17%, 34/205, 29%, 178/620, respectively), 182 
and defined daily doses (17%, 34/205, 25%, 156/620, respectively). In the community setting, commonest 183 
reported clinical outcomes were revisits (11%, 22/205), clinical cure (6%,12/205), and infection (5%, 184 
10/205), while in the hospital setting these were mortality (32%, 302/620), length of stay (32%, 201/620), 185 
and hospital readmissions (12%, 76/620).  186 
 187 
Quality features 188 
The percentage of studies including each quality feature is shown in Table 3. Studies in the community 189 
setting fulfilled a median of 5 quality features (IQR 3-7), while studies in the hospital setting fulfilled 3 (IQR 190 
2-4). None fulfilled all 10 quality features. In the community setting 2% (4/205) fulfilled 9, 16% (33/205) 191 
fulfilled at least 8, and 35% (72/205) fulfilled at least 7 quality indicators. In the hospital setting 1% (4/620) 192 
fulfilled 9, 3% (19/620) fulfilled 8, and 6% (37/620) fulfilled 7 quality indicators. Of note, there were 193 
substantial differences between studies which did and did not use randomised designs to the extent to 194 
which other quality features were present. Among the 150 randomised studies, all used an external 195 
control group, 71% (107/150) included multiple centres, 64% (97/150) reported a sample size calculation 196 
and 96% (144/150) collected data prospectively. In contrast, among the non-randomised studies, xx% 197 
(xx/xx) used an external control group, 21% (142/675) included multiple centres, 11% (76/675) reported a 198 
sample size calculation and 43% (288/675) collected data prospectively. 199 
 200 
Contingencies associated with design quality 201 
Design quality was considerably better in almost all quality aspects ofcommunity versus hospital setting 202 
studies (Figure S1A), with more use of randomised designs (46% vs. 9%), external controls (49% vs. 203 
11%), sample size calculations (38% vs. 15%), prospective data collection (70% vs. 46%), correction for 204 
confounding (55% vs. 25%), use of a defined primary outcome (57% vs. 44%), and involvement of 205 
multiple centres (72% vs. 16%). However, community setting studies less often reported clinical (30% vs. 206 
54%) and microbiological (8% vs. 28%) outcomes. Community setting remained significantly associated 207 
with all these contingencies in multivariable models (Table 4). From the studies that reported financial 208 
support, 20% (53/264) were industry funded, and 84% (221/264) were publicly funded. Studies with 209 
financial support were of higher methodological quality than studies without (Figure S1B), as they more 210 
frequentlyused randomised designs (31% vs. 7%), external controls (34% vs. 8%), sample size 211 
calculations (33% vs. 11%), prospective data collection (63% vs 43%), correction for confounding (46% 212 
vs. 21%), a defined primary outcome (56% vs. 39%), and involved multiple centres (46% vs. 16%). 213 
Financial support remained significantly associated with these contingencies in multivariable models 214 
(tTable 4). In addition, financial support increased the frequency of reporting clinical outcomes in 215 
multivariable models. There was little change in design quality over time, other than a decrease in the 216 
proportion of studies with prospective data collection ((77% in 1977-2004, 67% in 2005-2010, 42% in 217 
2011-2013, 40% in 2014-2015, 39% in 2016-2017) and an increase in studies reporting a clinical 218 
outcome (39% in 1977-2004, 44% in 2005-2010, 44% in 2011-2013, 53% in 2014-2015, 59% in 2016-219 
2017)) (Figure S1D). These outcomes were significantly associated with calendar time in multivariable 220 
models (Table 4), and sample size calculations were independently reported more in later studies. There 221 
were no large differences between studies performed in children versus adults (Figure S1C). 222 
Geographical region was independently associated with randomised designs, using an external control, 223 
prospective data collection, performing sample size calculations, reporting a primary, clinical or 224 
microbiological outcome, and being multicentre (Table 4). 225 
 226 
DISCUSSION 227 
In current systematic reviews on antimicrobial stewardship evaluations, many studies are excluded due to 228 
not fulfilling minimal methodological quality criteria. We have undertaken the first comprehensive 229 
systematic review that focused on describing quality, rather than excluding studies based on quality, to 230 
facilitate formulating recommendations for improvement. In addition, we evaluated quality features 231 
required for validity and translation into practice instead of focusing solely on methodological quality. Our 232 
systematic review revealed that the design quality of antimicrobial stewardship evaluations is low, with 233 
only a minority of studies reporting clinical and microbiological outcome data. Design quality is 234 
considerably better in studies performed in the community setting. 235 
We find published evaluations provide a striking lack of evidence for the clinical and microbiological 236 
impacts of antimicrobial stewardship interventions. The majority of studies focus exclusively on process 237 
measures. While it is clearly essential to establish whether an intervention is effective in changing 238 
antibiotic use, reporting clinical outcomes is crucial to assess the safety of antimicrobial stewardship 239 
interventions [15,16]. The clinical outcomes reported often utilise routinely collected data, which may 240 
explain the differences between the community and hospital setting. In particular, in the hospital setting, 241 
commonly used clinical outcomes are mortality and length of hospital stay [17,18]. As indicated by the 242 
observed time trends, these outcomes are being used with increasing frequency, probably because 243 
extraction of relevant data from electronic health records is becoming more feasible. Such routinely 244 
available data are not the most sensitive and patient-relevant outcomes. In the hospital setting, markers 245 
of early treatment response such as clinical stability may be preferable. In the community setting, repeat 246 
consultations, relapse of infection, and hospital admissions may be more relevant; yet data on these 247 
outcomes are not routinely collected [19–21].  248 
Very few stewardship studies report microbiological outcomes. This is  suprising given that reducing 249 
antimicrobial resistance is the ultimate goal of antimicrobial stewardship. However, this is consistent with 250 
a meta-analysis on the effect of stewardship interventions on infection and colonisation with antibiotic-251 
resistant bacteria and Clostridium difficile infections that showed the literature on this topic is sparse and 252 
dominated by low quality research [22]. Some authorities have called for stewardship evaluations to 253 
routinely include consideration of the impact of stewardship on resistance [23] but studies generally lack 254 
power to determine this. Relationships between antimicrobial exposure and resistance may be more 255 
efficiently established through specific mechanistic studies rather than within stewardship evaluations.  256 
Our analysis demonstrates that contingencies that would be expected to effect study design do, whiles 257 
others do not. The contrast between the community and hospital setting is striking in terms of the greater 258 
use of multicentre, randomised controlled designs.  One explanation could be that clusters required for 259 
cluster randomisation are more readily available in the community setting. In contrast, clinical outcomes 260 
and microbiological data are less readily available in the community setting. Retrospective study designs 261 
are therefore less feasible in the community setting.  262 
Financial support was associated with better design quality. In addition to the costs inherent to conducting 263 
multicentre, prospective studies with longer follow-up, the process of securing funding may drives careful 264 
consideration of study validity. Less than half of the stewardship studies reviewed reported external 265 
funding. However, our finding of an association between external funding and improved design quality 266 
underscore the necessity of external funding to support appropriate implementation and robust evaluation 267 
of antimicrobial stewardship programmes [24]. 268 
Our results show that there is no improvement of design quality over time, which is in contrast to previous 269 
reports. This can be explained by our evaluation  and inclusion of all studies without a pre-selection on 270 
study design..  271 
In keeping with previous reports we find that the majority of antimicrobial stewardship studies used non-272 
randomised research designs, with before-after studies being the most prevalent. This quasi-experimental 273 
research design is commonly used for quality improvement projects. However, such studies are at risk 274 
from multiple forms of bias [15,23,25] and the Effective Practice and Organisation of Care (EPOC) criteria 275 
stongly discourages the inclusion of before-after studies without an ITS analysis in systematic 276 
reviews[13]. Incorportation of properly conducted ITS analysis into before-after studies has the potential 277 
to robustly control for time-dependent bias [26] but only 20% (104/515) of before-after studies we 278 
identified used ITS analysis. Moreover, it has been shown that contemporary ITS analyses are often 279 
performed with an insufficient number of data points [11].  280 
This systematic review has several strengths. First, our comprehensive search strategy gives a unique 281 
overview of the quality of studies evaluating antimicrobials stewardship interventions. Second, we used 282 
the PRISMA reporting guide for systematic reviews [27]. Third, the quality indicators and candidate 283 
contingencies were selected in a consensus procedure as part of a Joint Programming Initiative on 284 
Antimicrobial Resistance (JPIAMR) funded consensus group, which was selected to both include experts 285 
on the field of antimicrobial stewardship and trial methodology. Finally, this is the first comprehensive 286 
systematic review to determine the extent to which published antimicrobial stewardship evaluations 287 
include quality features required for validity and translation into practice .  288 
The limitations of our review  were firstly, we only searched PubMed and excluded non-English studies, 289 
which makes it possible that antimicrobial stewardship studies indexed elsewhere and non-English 290 
studies were missed. However, if we compare the studies identified by our searching strategy with the 291 
largest community and hospital stewardship systematic reviews, only 6 studies were missed due to being 292 
indexed elsewhere and 11 due to being non-English. Therefore, thisis likely to have had a minimal impact 293 
on the total results. Secondly, the screening, inclusion, and data extraction was performed by only one 294 
investigator that could have resulted in studies being missed, wrongly included or misclassification of the 295 
extracted data. To estimate the amount of studies that might be missed, a proportion of the studies were 296 
screened and data was extracted by a second author. In this second round, we showed that the 297 
percentage of agreement was high, with a moderate interobserver agreement. Assuming that every 298 
disagreement in included studies would have inadvertently excluded a study (1% of 700 studies reviewed 299 
twice), we may have missed a maximum of 104 inclusions in the other studies not screened twice. In a 300 
systematic review with meta-analysis the consequence of missing or wrongly including a single study 301 
could have a large impact on the pooled effect estimate. However, as we did not focus on the outcome of 302 
individual studies but rather on the design quality of many studies, given the large number of studies 303 
included, it is unlikely that the missed studies would have changed the conclusions.  304 
Concerns about the methodological quality of antimicrobial stewardship studies have been raised before, 305 
with several publications making recommendations to improve their scientific methods [15,23,25]. 306 
However, thus far we observed no improvement in methodological quality over time except for more 307 
frequent inclusion of sample size calculation and clinical outcomes. Therefore, there is still a need for 308 
clear recommendations to improve antimicrobial stewardship design quality. Recommendations for 309 
improvement should especially consider: (1) emphasizing the importance of choosing appropriate clinical 310 
and microbiological outcomes, (2) focusing on robust methods to evaluate stewardship interventions in 311 
the hospital setting.Implementing these recommendations in future antimicrobial stewardship studies will 312 
help in the optimal use of resources to determine which stewardship interventions are most effective to 313 
change clinical practice. Building on the work from the systematic review we established a working group 314 
of expert investigators in this field. This systematic review identifies the limitations in design features that 315 
are most important for validity and translation into clinical practice. The results will be used to formulate 316 
recommendations in a white paper that will support investigators with key design decisions, support 317 
funders assessing proposals for stewardship studies and enhance the quality and impact of research in 318 
this crucial area.  319 
 320 
SUPPORT STATEMENT 321 
The presented work was supported by a grant (JPIAMRWG-010) from the Joint Programming Initiative on 322 
Antimicrobial Resistance. 323 
 324 
ACKNOWLEDGMENTS 325 
Other members of the Consensus on Antimicrobial Stewardship Evaluations (CASE) study group: 326 
S.Harbarth, B. Huttner, P. Little, J. Rodriguez-Baño, A. Savoldi, M. van Smeden, E. Tacconelli, J.F. 327 
Timsit, M. Wolkewitz. 328 
Part of these data were presented at the 28th ECCMID 2018 in Madrid, Spain, 21-24 of April 2018 329 
(#O0530). 330 
 331 
CONFLICT OF INTEREST 332 
The authors declare no conflict of interest.  333 
Figure 1. Flowchart of the studies included in the systematic literature review 334 
 335 
 336 
  337 
Table 1. Characteristics of included studies stratified by studies performed in the community and the 338 
hospital setting 339 
 
Study characteristics 
Community 
(n=205) 
n (%) 
Hospital 
(n=620) 
n (%) 
Number of patients included (median, IQR) 1255 (278-11230) 423 (186-1398) 
Number of centres involved (median, IQR) 27 (8-90) 1 (1-1) 
Age   
 Adults 64 (31) 285 (46) 
 Children 33 (16) 68 (11) 
 Both 108 (53) 267 (43) 
Specific disease targeted   
 No specific disease targeted 63 (31) 342 (55) 
 Upper respiratory tract infections 106 (52) 25 (4) 
 Lower respiratory tract infections 57 (28) 70 (11) 
 Bacteraemia 0 (0) 42 (7) 
 Urinary tract infections 18 (9) 27 (4) 
 Prophylaxis 2 (1) 39 (6) 
 Sepsis 0 (0) 17 (3) 
 Skin and soft tissue infections 1 (1) 8 (1) 
 Abdominal infections 3 (1) 10 (2) 
 Other 16 (8) 62 (10) 
Antibiotic class targeted   
 No specific antibiotic class targeted 177 (86) 427 (69) 
 Cephalosporins 4 (2) 66 (11) 
 Fluoroquinolones 10 (5) 54 (9) 
 Carbapenems 0 (0) 48 (8) 
 Vancomycin 0 (0) 31 (5) 
 Aminoglycosides 0 (0) 28 (5) 
 Penicillins 10 (5) 15 (2) 
 Macrolides 8 (4) 5 (1) 
 Other 17 (8) 89 (14) 
Antimicrobial stewardship interventions   
 Education 149 (73) 260 (42) 
 Audit and feedback – individual patient 12 (6) 245 (40) 
 Audit and feedback – periodic 59 (29) 82 (13) 
 Restriction 13 (6) 113 (18) 
 Clinical decision support 31 (15) 112 (18) 
 Rapid diagnostic testing 24 (12) 68 (11) 
 Therapeutic drug monitoring 0 (0) 15 (2) 
 Guideline implementation 20 (10) 95 (15) 
 Delayed prescribing 9 (4) 0 (0) 
 Other 42 (20) 78 (13) 
Research designs   
 Before-after study 48 (23) 365 (59) 
 Before-after study (ITS*) 22 (11) 82 (13) 
 Cohort without control group  6 (3) 75 (12) 
 Controlled before-after study 22 (11) 19 (3) 
 Randomised controlled trial (RCT) 28 (14) 40 (6) 
 Parallel cluster randomised trial 30 (15) 6 (1) 
 Parallel cluster randomised trial with baseline period 26 (13) 2 (1) 
 Controlled before-after study (ITS) 7 (3) 12 (2) 
 Non-randomised parallel cluster study 5 (2) 8 (1) 
 Factorial cluster randomised trial 7 (3) 0 (0) 
 Cluster randomised cross-over trial 2 (1) 3 (1) 
 Stepped wedge cluster randomised trial 0 (0) 1 (1) 
 Non-randomised cluster cross-over study 0 (0) 3 (1) 
 Factorial randomised controlled trial (RCT) 1 (1) 2 (1) 
 Non-randomised stepped wedge study 0 (0) 2 (1) 
 Adaptive RCT 1 (1) 0 (0) 
IQR: interquartile range, *ITS: interrupted time series  340 
Table 2. Outcomes reported in the included antimicrobial stewardship studies stratified by studies 341 
performed in the community and the hospital setting 342 
Process measure outcomes Community 
(n=205) 
n (%) 
Hospital 
(n=620) 
n (%) 
 Costs/cost-effectiveness 36 (18) 200 (32) 
 Appropriateness 34 (17) 178 (29) 
 Defined daily doses (DDD) 34 (17) 156 (25) 
 Proportion treated with antibiotics 121 (59) 131 (21) 
 Recommendation acceptance 6 (3) 114 (18) 
 Guideline adherence 27 (13) 100 (16) 
 Duration of treatment 5 (2) 93 (15) 
 Days on therapy (DOT) 6 (3) 62 (10) 
 Time to appropriate therapy 3 (1) 71 (11) 
 Antibiotic knowledge 17 (8) 14 (2) 
 None 2 (1) 5 (1) 
 Other 58 (28) 166 (27) 
Clinical outcome measures   
 None 144 (70) 283 (46) 
 Mortality 9 (4) 203 (33) 
 Length of stay 5 (2) 201 (32) 
 Infection 10 (5) 75 (12) 
 Hospital readmission 0 (0) 76 (12) 
 Adverse effects 5 (2) 52 (8) 
 Revisits 22 (11) 0 (0) 
 Clinical cure 12 (6) 27 (4) 
 Intensive care unit admission 0 (0) 24 (4) 
 Hospital admission 9 (4) 0 (0) 
 Time to clinical stability 3 (1) 6 (1) 
 Other 16 (8) 49 (8) 
Microbiological outcome measures   
 None 188 (92) 447 (72) 
 Colonization/infection resistant pathogens 17 (8) 146 (24) 
 Clostridium difficile infections 5 (2) 62 (10) 
 Other 2 (1) 12 (2) 
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Table 3. Design quality features of the included studies stratified by studies performed in the community 344 
and the hospital setting 345 
Quality feature Community 
(n=205) 
n (%) 
Hospital 
(n=620) 
n (%) 
Randomised research design 95 (46) 55 (9) 
External control group 100 (49) 68 (11) 
Multicenter 148 (72) 101 (16) 
Sample size calculation reported 77 (38) 96 (15) 
Prospective data collection 144 (70) 288 (46) 
Correction for confounding factors 113 (55) 157 (25) 
Primary outcome defined 116 (57) 272 (44) 
Clinical outcome reported 61 (30) 337 (54) 
Microbiological outcome reported 17 (8) 173 (28) 
Sustainability assessed (≥12 months) 115 (56) 347 (56) 
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Table 4. Results of stepwise backward selection of multivariable model containing all the contingencies with the different design quality indicators 
as outcome. The colors indicate either a strong negative association (OR<1.0) in red, or a strong positive association (OR>1.0) in green. Numbers 
indicate odds ratio’s with 95% confidence intervals 
 
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8 Model 9 Model 10
Randomised 
design
External control Sample size 
calculation
Prospective data Confounding 
correction
Primary 
outcome
Clinical outcome Microbiological 
outcome
Multicentre Sustainability 
assessed
Clinical setting Community 5.9 (3.8 - 9.2) 5.6 (3.6 - 8.5) 2.9 (1.9 - 4.5) 1.7 (1.2 - 2.6) 3.0 (2.1 - 4.3) 1.4 (1.0 - 2.0) 0.3 (0.2 - 0.5) 0.2 (0.1 - 0.4) 10.5 (7.1 - 15.7)
Financial support Yes 4.7 (2.9 - 7.5) 4.1 (2.6 - 6.3) 3.1 (2.1 - 4.7) 2.2 (1.6 - 3.0) 2.5 (1.8 - 3.4) 1.8 (1.4 - 2.5) 1.9 (1.4 - 2.6) 3.0 (2.0 - 4.3)
Age group studied** Children 1.1 (0.6 - 2.2) 0.8 (0.4 - 1.6) 0.8 (0.5 - 1.4) 1.1 (0.7 - 1.9) 1.0 (0.6 - 1.6) 0.6 (0.4 - 1.0) 1.4 (0.9 - 2.2)
Both 0.6 (0.4 - 1.0) 0.6 (0.4 - 0.9) 0.4 (0.2 - 0.6) 0.5 (0.4 - 0.7) 0.5 (0.4 - 0.7) 0.4 (0.3 - 0.5) 1.6 (1.2 - 2.2)
Year study conducted*** 2005-2010 1.0 (0.5 - 1.9) 1.1 (0.6 - 1.9) 2.5 (1.3 - 4.8) 0.4 (0.2 - 0.6) 0.6 (0.4 - 1.0) 0.9 (0.6 - 1.5) 2.1 (1.2 - 3.7) 1.1 (0.7 - 1.8)
2011-2013 0.5 (0.3 - 1.1) 0.5 (0.2 - 0.9) 1.8 (0.9 - 3.5) 0.2 (0.1 - 0.3) 0.7 (0.4 - 1.2) 1.0 (0.6 - 1.6) 1.7 (1.0 - 3.0) 1.6 (1.0 - 2.5)
2014-2015 0.4 (0.2 - 0.8) 0.5 (0.2 - 0.9) 2.5 (1.3 - 4.9) 0.1 (0.1 - 0.2) 1.1 (0.7 - 1.8) 1.3 (0.8 - 2.1) 1.2 (0.7 - 2.1) 1.8 (1.1 - 2.8)
2016-2017 0.8 (0.4 - 1.5) 0.9 (0.5 - 1.7) 2.5 (1.3 - 4.9) 0.1 (0.1 - 0.2) 1.2 (0.7 - 1.9) 1.7 (1.0 - 2.7) 1.4 (0.8 - 2.4) 1.2 (0.8 - 1.8)
Geographical region**** Europe 2.5 (1.5 - 4.2) 2.2 (1.4 - 3.5) 1.6 (1.1 - 2.5) 2.8 (1.9 - 4.1) 1.1 (0.8 - 1.5) 1.1 (0.8 - 1.6) 0.9 (0.6 - 1.4) 2.0 (1.3 - 3.1)
Asia 2.6 (1.3 - 5.0) 2.4 (1.3 - 4.4) 1.1 (0.6 - 2.0) 1.7 (1.1 - 2.7) 0.4 (0.3 - 0.7) 1.8 (1.1 - 2.8) 1.2 (0.8 - 2.0) 1.0 (0.6 - 1.8)
Oceania 1.6 (0.6 - 4.2) 1.5 (0.6 - 3.7) 0.5 (0.1 - 1.4) 1.8 (0.8 - 3.9) 0.5 (0.2 - 1.0) 0.5 (0.2 - 1.0) 0.2 (0.1 - 0.8) 0.9 (0.4 - 2.2)
Africa 4.0 (1.1 - 14.5) 3.3 (0.9 - 11.8) 1.8 (0.5 - 5.8) 2.0 (0.6 - 6.2) 0.9 (0.3 - 2.5) 1.8 (0.6 - 5.3) 0.2 (0.1 - 1.7) 7.2 (2.0 - 25.1)
South America 1.8 (0.4 - 7.4) 2.3 (0.6 - 8.4) 2.0 (0.6 - 6.5) 2.2 (0.8 - 6.4) 1.1 (0.4 - 2.9) 1.1 (0.4 - 3.0) 1.3 (0.4 - 3.8)
*Reference category: studies performed in the hospital setting, **Reference category: studies performed in adults, ***Reference category: studies performed before 2005, ****Reference category: studies performed in North America
Strong negative association Weak association Strong positive association
Design quality indicators
Contingencies
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SUPPLEMENT 
Table S1. Definition of the methodological quality determinants used and corresponding categorisation if 
applicable 
Methodological 
quality indicator 
Definition Categorisation (if applicable) 
Randomised research 
design 
Allocation of the antimicrobial stewardship 
intervention or comparator was random.  
Randomised:  
RCT, c-RCT, cx-RCT, sw-CRT 
Non-randomised: 
BA(with or without ITS 
analysis), cBA, cohort studies, 
non-randomised trials 
External control group The outcome was also assessed in an 
external control group without antimicrobial 
stewardship intervention. External indicates 
that a contemporary cluster or group is 
included in which the intervention under 
study is not implemented. 
Parallel control group:  
cBA, RCT, non-randomised 
trials, c-RCT, cx-RCT, sw-CRT 
No parallel control group:  
BA, cohort studies 
Number of centres Amount of centres involved in the study, 
either as control or intervention. 
Singlecentre: 0-1 centre 
 
Multicenter: >1 centre 
Sustainability of the 
intervention 
sufficiently assessed 
The duration of follow-up of the cluster after 
the intervention was introduced to assess the 
sustainability of the intervention 
Yes: 
Duration of follow-up ≥12 
months 
No:   
Duration of follow-up <12 
months 
Sample size 
calculation reported 
A sample size calculation was performed to 
ensure sufficient power for the primary 
outcome.  
- 
Prospective data 
collection 
The data was prospectively collected. If not 
reported we assumed the data collection to 
be retrospective. 
- 
Confounding 
correction 
The intervention effect was corrected for 
confounding bias, either by randomisation, 
matching, stratification or correction.  
- 
Primary outcome A primary outcome was clearly defined. - 
defined 
Clinical outcome 
reported 
Any clinical outcome was reported. Clinical 
outcomes include mortality, length of stay, 
readmissions, revisits, etc. 
- 
Microbiological 
outcome reported 
Any microbiological outcome was reported. 
Microbiological outcomes include CDI, 
colonisation or infection with antimicrobial 
resistant bacteria 
- 
RCT: randomised controlled trial, c-RCT: parallel cluster randomised controlled trial, cx-RCT: cluster 
cross-over randomised controlled trial, sw-CRT: stepped wedge cluster randomised trial, BA: before-after 
study, cBA: controlled before-after study, ITS: interrupted time-series, CDI: Clostridium difficile infection 
  
Table S2.  
Community      1977-
2004 
     2005-
2010 
     2011-
2013 
     2014-
2015 
     2016-
2017 
Randomised design 10% 17% 6% 6% 8% 
External control 12% 20% 6% 8% 11% 
Sample size calculation 8% 21% 13% 18% 17% 
Multicentre 9% 14% 18% 20% 18% 
Prospective data 71% 68% 37% 36% 31% 
Confounding correction 24% 22% 19% 29% 30% 
Primary outcome 38% 50% 37% 45% 48% 
Clinical outcome 43% 51% 50% 58% 66% 
Microbiological outcome 21% 38% 32% 23% 27% 
Sustainability assessed 53% 50% 55% 65% 54%       
Hospital 
     
Randomised design 43% 47% 41% 41% 61% 
External control 45% 51% 41% 45% 65% 
Sample size calculation 19% 44% 35% 48% 52% 
Multicentre 68% 75% 78% 69% 71% 
Prospective data 89% 65% 57% 59% 74% 
Confounding correction 58% 42% 54% 66% 65% 
Primary outcome 53% 53% 59% 66% 58% 
Clinical outcome 32% 29% 27% 31% 29% 
Microbiological outcome 6% 5% 8% 17% 10% 
Sustainability assessed 43% 56% 78% 55% 52% 
  
Figure S1. Design quality indicators stratified by: (A) community versus hospital setting, (B) financial 
support versus no financial support, (C) age setting: children, adults or both, (D) old versus new studies, 
(E) geographical region 
 
 
  
  
  
   
 
